- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Kaken Pharmaceutical Co Ltd (4521)Kaken Pharmaceutical Co Ltd stock price live, this page displays TYO 4521 stock exchange data. View the 4521 premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Kaken Pharmaceutical Co Ltd real time stock price chart below.
What Is the Kaken Pharmaceutical Co Ltd Stock Price Today?
The Kaken Pharmaceutical Co Ltd stock price today is 4,336.0.
What Is the Stock Symbol for Kaken Pharmaceutical Co Ltd?
The stock symbol for Kaken Pharmaceutical Co Ltd is "4521."
What Stock Exchange Does Kaken Pharmaceutical Co Ltd Trade On?
Kaken Pharmaceutical Co Ltd is listed and trades on the Tokyo stock exchange.
Is Kaken Pharmaceutical Co Ltd a Good Stock to Buy?
Determining whether Kaken Pharmaceutical Co Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the 4521 quote. (ISIN: JP3207000005)
What Is the Kaken Pharmaceutical Co Ltd Stock Price Today?
The Kaken Pharmaceutical Co Ltd stock price today is 4,336.0.
What Is the Stock Symbol for Kaken Pharmaceutical Co Ltd?
The stock symbol for Kaken Pharmaceutical Co Ltd is "4521."
What Stock Exchange Does Kaken Pharmaceutical Co Ltd Trade On?
Kaken Pharmaceutical Co Ltd is listed and trades on the Tokyo stock exchange.
Is Kaken Pharmaceutical Co Ltd a Good Stock to Buy?
Determining whether Kaken Pharmaceutical Co Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the 4521 quote. (ISIN: JP3207000005)
Tokyo
Currency in JPY
4,336.0
-46.0(-1.05%)
Delayed Data
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4,325.0
4,403.0
52 wk Range
3,161.0
4,577.0
4521 Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
High dividend Yield
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4,325.04,403.0
52 wk Range
3,161.04,577.0
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(4.34%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
UnlockEV/EBITDA
UnlockBeta
Book Value / Share
UnlockPrev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(4.34%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
UnlockEV/EBITDA
UnlockBeta
Book Value / Share
Unlock4521 Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceFair Price
Upside
Technical Analysis
Neutral
Analysts Sentiment
Neutral
Price Target
4,850.0
Upside
+11.9%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Valuation implies a strong free cash flow yield
Kaken Pharmaceutical Co Ltd Company Profile
Kaken Pharmaceutical Co., Ltd. produces, markets, and sells medical products, medical devices, and agrochemicals in Japan and internationally. The company offers pharmaceutical products and medical devices, such as Clenafin, a topical treatment for onychomycosis; Artz, an anti-osteoarthritis agent; Fiblast, a wound-healing agent; Ecclock for the treatment of primary axillary hyperhidrosis; Regroth, a periodontal regenerative agent; Hernicore for the treatment of lumbar disc herniation; and Seprafilm, an adhesion barrier used primarily in surgery and gynecology to reduce complications from post-operative adhesions. It also provides agrochemicals and animal health products, including Polyoxins that is used as fungicide; Pentoxazone and Metamifop rice herbicides; and Salinomycin, an anti-coccidial feed additive for chickens. In addition, the company is developing KMW-1 for the removal of eschar; KAR, which is in phase III clinical trial for the treatment of head lice; KP-001 that is in phase II clinical trial for the treatment of refractory vascular malformations; BBI-4000 that is in phase I clinical trial for primary palmoplantar hyperhidrosis; KP-483, which is in phase I clinical trial for the treatment of solid tumors; NM26-2198 that is in phase I clinical trial for the treatment of atopic dermatitis; KP-910, which is in phase I clinical trial for peripheral neuropathic pain; Seladelpar that is in phase I clinical trial for primary biliary cholangitis; and Tildacerfont, which is in phase I clinical trial for congenital adrenal hyperplasia. Further, it is involved in the rental of Bunkyo Green Court. Kaken Pharmaceutical Co., Ltd. was founded in 1917 and is headquartered in Tokyo, Japan.
Compare 4521 to Peers and Sector
Metrics to compare | 4521 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship4521PeersSector | |
|---|---|---|---|---|
P/E Ratio | 9.0x | 15.1x | −0.6x | |
PEG Ratio | 0.02 | 0.18 | 0.00 | |
Price/Book | 1.1x | 1.2x | 2.6x | |
Price / LTM Sales | 1.9x | 1.5x | 3.2x | |
Upside (Analyst Target) | 10.9% | 16.7% | 46.2% | |
Fair Value Upside | Unlock | 19.4% | 7.0% | Unlock |
Analysts' Recommendations
1 Buy
1 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 4,850.0
(+11.85% Upside)
Dividends
Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 481.73
Dividend Yield
4.37%
Industry Median 2.25%
Annualised payout
190
Paid unevenly
5-Years Growth
-
Growth Streak
FAQ
What Is the Kaken Pharmaceutical Co Ltd (4521) Stock Price Today?
The Kaken Pharmaceutical Co Ltd stock price today is 4,336.00.
What Stock Exchange Does Kaken Pharmaceutical Co Ltd Trade On?
Kaken Pharmaceutical Co Ltd is listed and trades on the Tokyo stock exchange.
What Is the Stock Symbol for Kaken Pharmaceutical Co Ltd?
The stock symbol for Kaken Pharmaceutical Co Ltd is "4521."
Does Kaken Pharmaceutical Co Ltd Pay Dividends? What’s The Current Dividend Yield?
The Kaken Pharmaceutical Co Ltd dividend yield is 4.34%.
What Is the Kaken Pharmaceutical Co Ltd Market Cap?
As of today, Kaken Pharmaceutical Co Ltd market cap is 164.34B.
What is Kaken Pharmaceutical Co Ltd Earnings Per Share?
The Kaken Pharmaceutical Co Ltd EPS is 481.73.
What Is the Next Kaken Pharmaceutical Co Ltd Earnings Date?
Kaken Pharmaceutical Co Ltd will release its next earnings report on 30 Jan 2025.
From a Technical Analysis Perspective, Is 4521 a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.